Marta Banchi

6PUBLICATIONS
15CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)HaematologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 12, 2026
Prognostic Circulating Cytokine Panels for Metronomic Chemotherapy in Metastatic Gastrointestinal Cancer: Exploratory Pharmacodynamic Biomarker Analysis of the Phase II COMET Trial.

|Jan 28, 2026
Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis.

Sabrina Pelliccia, Marta Banchi, Lucrezia De Marchi

|Oct 29, 2025
Pharmacokinetics and Monitoring of Methotrexate in Adults with Acute Lymphoblastic Leukaemia: A 10-Year Follow-Up at an Italian Centre.

Pasquale Fabio Calabrò, Letizia Biso, Marianna Lastella

|Apr 02, 2025
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway.

Marta Banchi, Maria Christina Cox, Paola Orlandi

|Feb 26, 2025
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo.

Arianna Bandini, Marta Banchi, Paola Orlandi

|Jan 17, 2025
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway.

Marta Banchi, Maria Christina Cox, Arianna Bandini

Pageof 1

Frequent Collaborators

4 joint publications

Guido Bocci

3 joint publications

Arianna Bandini

1 joint publications

Greta Alì

1 joint publications

Eleonora Vandini